Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Baton Rouge, Louisiana 70808


This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity. The purpose of this study is to obtain a preliminary assessment of the safety and efficacy of APD356, when administered daily for 12 weeks, in obese subjects who are otherwise healthy. Subjects who are on concomitant medications for control of hypertension or blood lipids may qualify.

Study summary:

This is a double-blind, placebo-controlled, randomized, parallel group study. Three different doses of APD356 or placebo will be administered daily for 12 weeks, to obese, male and nonpregnant, nonlactating, female volunteers, aged 18 to 65 years. Approximately 400 subjects will be enrolled.


Inclusion Criteria: - Healthy male or nonpregnant, nonlactating females aged 18-65 years (inclusive) - Body mass index (BMI) of 30-45 kg/m2 - Non-smoker - No concomitant medications other than hypertension medications (stable > 90 days) and/or statins (stable > 90 days) - No past treatment with drugs associated with the development of pulmonary hypertension or cardiac valvular insufficiency - No more than mild mitral valve regurgitation and absence of aortic valve regurgitation upon screening echocardiogram



Primary Contact:

Study Chair
William R Shanahan, Jr., MD
Arena Pharmaceuticals

Backup Contact:


Location Contact:

Baton Rouge, Louisiana 70808
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.